grant

EcoHIV and neuropathic pain

Organization UNIVERSITY OF TEXAS RIO GRANDE VALLEYLocation EDINBURG, UNITED STATESPosted 15 Sept 2023Deadline 31 Aug 2026
NIHUS FederalResearch GrantFY202465 and older65 or older65 years of age and older65 years of age or more65 years of age or older65+ years65+ years oldAIDS VirusAcquired Immune Deficiency Syndrome VirusAcquired Immunodeficiency Syndrome VirusAcuteAddressAdherenceAffectAgeAged 65 and OverAllergyAnalgesic AgentsAnalgesic DrugsAnalgesic PreparationAnalgesicsAnimal ModelAnimal Models and Related StudiesAnimalsAnodynesAntinociceptive AgentsAntinociceptive DrugsAreaBehaviorBehavior assessmentBehavioralBiochemistryBiologicalBiological ChemistryCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCell BodyCellsCharacteristicsChronicClinicalClinical DataCognitive deficitsDNADNA Molecular BiologyDeoxyribonucleic AcidDermatologic biopsyDevelopmentDifferences between sexesDiffers between sexesDysesthesiasEnsureEsthesiaFemaleGene TranscriptionGenetic TranscriptionGlycoproteinsHIVHIV 1 associated neurocognitive disorderHIV InfectionsHIV associated neurocognitive deficitHIV associated neurocognitive impairmentHIV diagnosisHIV induced neurocognitive deficitHIV induced neurocognitive impairmentHIV neurocognitive impairmentHIV-1HIV-1 associated neurocognitive deficitHIV-1 associated neurocognitive disorderHIV-1 associated neurocognitive impairmentHIV-IHIV-associated neurocognitive disorderHIV1HTLV-III InfectionsHTLV-III-LAV InfectionsHealthHistopathologyHuman Immunodeficiency Virus Type 1Human Immunodeficiency VirusesHuman T-Lymphotropic Virus Type III InfectionsHuman immunodeficiency virus 1HypersensitivityIP injectionIndividualInfectionInjectionsIntraperitoneal InjectionsKnowledgeLAV-HTLV-IIILightLongitudinal StudiesLymphadenopathy-Associated VirusMaintenanceMedulla SpinalisMental DepressionMesencephalic Central GrayMiceMice MammalsMidbrain Central GrayModelingMolecular BiologyMurineMusNeedlesNerve FibersNeurocognitive Impairment in HIVNeurocognitive Impairment in HIV-1NeuropathyOutcomePNS DiseasesPainPainfulPathologicPatientsPeriaqueductal GrayPeripheral Nerve DiseasesPeripheral Nervous System DiseasesPeripheral Nervous System DisordersPeripheral NeuropathyPersistent painPersonsPharmacologyPhotoradiationPhysical FunctionPrevalenceProteinsQOLQuality of lifeRNA ExpressionReceptor ProteinReportingResearchRoleSensationSensorySeveritiesSex DifferencesSexual differencesSpinal CordStimulusT4 CellsT4 LymphocytesTestingTherapeuticTherapeutic StudiesTherapy ResearchTouchTouch sensationTrans-Acting FactorsTrans-ActivatorsTransactivatorsTranscriptionTranscription ActivatorTranscription CoactivatorTranscription Factor CoactivatorTranscriptional ActivatorTranscriptional Activator/CoactivatorTranscriptional CoactivatorVaccinesViralViral Gene ProductsViral Gene ProteinsViral ProteinsVirus-HIVabove age 65access to health careaccess to healthcareaccessibility of health careaccessibility to health careaccessibility to healthcareafter age 65age 65 and greaterage 65 and olderage 65 or olderageage associated differenceage based differenceage dependent differenceage dependent variationage differenceage of 65 years onwardage related differenceage related variationage specific differenceaged 65 and greateraged 65+aged ≥65agesallodyniaannulus of the aqueductantiretroviral therapyantiretroviral treatmentapproach behaviorbehavior testbehavioral assessmentbehavioral testbiologicchronic neuropathic painchronic painco-morbidco-morbiditycognitive defectscomorbidityconstant paincostcutaneous biopsydensitydepressiondevelopmentaldiffer by agedifference across agedifference in agehealth care accesshealth care availabilityhealth care service accesshealth care service availabilityhealthcare accesshealthcare accessibilityhealthcare availabilityhealthcare service accesshealthcare service availabilityhuman old age (65+)interdisciplinary approachlasting painlong-term studylongitudinal outcome studieslongterm studymalemechanical allodyniamidbrain central gray substancemodel of animalmultidisciplinary approachneural inflammationneuroinflammationneuroinflammatoryneuropathicneuropathic painold ageon-going painongoing painover 65 yearspain killerpain medicationpain modelpain relieverpain sensationpainful neuropathypainful sensationpainkillerperiaqueductal gray matterpharmacologicpublic health relevancereceptorresponsesexsex based differencessex-dependent differencessex-related differencessex-specific differencesside effectskin biopsysocial rolesubstance usesubstance usingtactile sensationtherapeutic agent developmenttherapeutic developmenttherapeutically effectivetooltranscription co-activatortranscriptional co-activatorvariation by agevirus protein≥65 years
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

PROJECT SUMMARY/ABSTRACT
Chronic pain is a major health condition in people living with Human Immunodeficiency Virus-1 (PLWH) despite

the use of combined antiretroviral therapy (ART). Unlike other human immunodeficiency virus (HIV) areas of

research (e.g., HIV-associated neurocognitive disorder, vaccine), chronic pain is an understudied area of

research despite the prevalence of pain in PLWH, lack of effective analgesic therapy, and incomplete

understanding of mechanisms. The development of therapeutic strategies and a better understanding of HIV-

related neuropathic pain mechanisms have been hampered by the lack of a suitable animal model that mimics

chronic neuropathic pain in PLWH. The current small animal model for HIV-related neuropathic pain consists of

the acute administration of a single HIV viral protein, such as glycoprotein 120 (gp120). This model has served

to determine the pain response to this viral protein and its mechanism of action. However, in addition to gp120,

other HIV viral proteins, HIV-1 transactivator of transcription (Tat), and Viral protein R (Vpr) can produce pain.

Therefore, a single HIV protein is unlikely to be the only contributor to HIV-neuropathic pain and mimics the HIV

chronic condition where there is a continuous presence of HIV and a simultaneous presence of viral proteins.

The proposed studies will test the hypothesis that EcoHIV-infected mice develop a neuropathic pain-like

condition with behavioral and pathological changes that mimic PLWH with chronic neuropathic pain. A

multidisciplinary approach of behavior, pharmacology, molecular biology, biochemistry, and histopathology will

test this hypothesis. Aim 1. We will perform comprehensive studies to characterize neuropathic pain in EcoHIV-

infected mice. We will use a battery of behavioral assessments of sensory and spontaneous/ongoing pain.

Analyzing markers clinically used for the diagnosis of HIV-associated peripheral neuropathy (e.g., decrease in

intraepidermal nerve fiber density) will serve to validate the EcoHIV-associated neuropathic pain model. We will

also analyze neuroinflammation, a key player in the induction and maintenance of chronic pain.

The proposed studies will have a significant impact on the fields of HIV and pain by providing a small animal

model to study HIV-related neuropathic pain, which has been lacking. Characterization of the EcoHIV-related

neuropathic pain model will advance current research on pain in the context of HIV by laying the groundwork for

urgently and critically needed studies.

Grant Number: 5R21NS134408-02
NIH Institute/Center: NIH

Principal Investigator: Khalid Benamar

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →